GLP-1s After 65: 10 Studies, and Not One Designed for Older Adults

The strongest age evidence available: a pre-specified pooled analysis of the two STEP-HFpEF trials, splitting 1,145 adults with obesity-related heart failure into under 65, 65 to 74, and 75 and over. Symptom scores, six-minute walk distance and weight improved consistently in all three bands, and the safety profile did not shift with age. ★ It is currently the only randomized evidence of this quality in people over 75, which is worth knowing given how often that group is the one in question.

PMID 41290376 ↗DOI 10.1002/ejhf.70049 ↗

The two semaglutide cardiovascular safety trials — injectable and oral — pooled and re-cut by baseline age across 6,480 participants with type 2 diabetes. Cardiovascular event reduction, A1C change and weight loss ran broadly parallel across the age bands, with no excess adverse events in the oldest. ⚠ Post hoc rather than pre-specified, which is a weaker footing, but it remains the most careful age-stratified safety read in the cardiovascular literature for this drug.

PMID 39520501 ↗DOI 10.1007/s13300-024-01659-7 ↗

A meta-analysis restricted to participants 65 and over, pooling randomized and observational studies to produce a single geriatric effect estimate. Weight and glucose effects came out comparable to general-adult trials, with one consistent difference: more people stopped because of gastrointestinal side effects. That gap matters clinically — the drug works as well and is tolerated less well, which is an argument for slower titration rather than for withholding it.

PMID 41640092 ↗DOI 10.1002/oby.70098 ↗

A systematic review asking whether these drugs work differently across demographic groups, age included. Relative weight loss was consistent across age bands, but absolute reductions were smaller in older participants — largely because they started lighter. ★ Worth understanding before reading a chart: 'less weight lost' and 'works less well' are different claims, and this analysis separates them.

PMID 41770554 ↗DOI 10.1001/jamainternmed.2025.8222 ↗

The clearest statement of the case for caution, drawing its body-composition numbers from the STEP, SURMOUNT and SUSTAIN trial programs and arguing that a lean-mass fraction of 25 to 40% means something different at 75 than at 45. Its point is not that the ratio is worse in older patients but that the reserve is smaller. It sets out who should be screened before starting and what to do about it — resistance training and protein intake — which is as far as the evidence currently supports going.

PMID 40819408 ↗DOI 10.1016/j.jnha.2025.100652 ↗

A perspective piece from a geriatric obesity-medicine researcher that does something the trial literature does not: propose an actual procedure. It suggests measuring grip strength and gait speed, and body composition where a scanner is available, before starting an incretin in someone over 65, and it frames the decision as a trade rather than a yes-or-no. ⚠ It is a proposal, not a validated protocol — no trial has tested whether screening this way improves outcomes.

PMID 40644314 ↗DOI 10.2337/dbi25-0004 ↗

A short editorial that names the three groups where lean-mass loss most plausibly crosses from a talking point into harm — the elderly, the frail, and anyone whose kidneys are already failing — and argues that body-composition measures should be standard endpoints in obesity drug development rather than optional substudies. It is opinion with no new data, and it has shaped how European guideline discussions frame the question.

PMID 41101588 ↗DOI 10.1016/j.diabet.2025.101708 ↗

A review focused on postmenopausal and older women, who make up a disproportionate share of Medicare-age prescriptions and are underrepresented in the discussion. It covers how body composition responds differently by sex, how bone loss after estrogen decline interacts with weight loss, and a structured protein-and-training protocol intended to limit lean-mass loss. Narrative rather than systematic, and the most directly practical entry here for that patient.

PMID 41754149 ↗DOI 10.3390/nu18040632 ↗

A pharmacist-authored case series working through the problems that actually arise in geriatric practice and appear in no trial: polypharmacy, declining kidney function, interactions with medications flagged as risky in older adults, and — the part usually missing — when to stop. Its discontinuation triggers, including unintended weight loss past a healthy point and progressing frailty, are the most concrete guidance on this page.

PMID 41966038 ↗DOI 10.4140/TCP.n.2026.78 ↗

An exploratory analysis of SELECT counting hospitalizations rather than cardiac events across its 17,604 participants — all carrying obesity plus existing heart disease, roughly a third of them 65 or over. Semaglutide reduced all-cause admissions, with cardiovascular admissions the standout. ⚠ Exploratory, so treat it as a signal. It matters mostly because hospitalization is the endpoint payers and health systems price coverage against, which makes it a policy document as much as a clinical one.

PMID 41433034 ↗NCT03574597 ↗DOI 10.1001/jamacardio.2025.4824 ↗